Virginia Retirement Systems ET AL acquired a new position in DaVita HealthCare Partners Inc. (NYSE:DVA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 32,700 shares of the company’s stock, valued at approximately $2,528,000.

Other large investors also recently made changes to their positions in the company. Chevy Chase Trust Holdings Inc. boosted its stake in shares of DaVita HealthCare Partners by 3.8% in the first quarter. Chevy Chase Trust Holdings Inc. now owns 139,937 shares of the company’s stock worth $10,269,000 after buying an additional 5,152 shares during the period. DnB Asset Management AS boosted its stake in shares of DaVita HealthCare Partners by 81.3% in the first quarter. DnB Asset Management AS now owns 18,510 shares of the company’s stock worth $1,358,000 after buying an additional 8,300 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its stake in shares of DaVita HealthCare Partners by 13.0% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 38,786 shares of the company’s stock worth $2,846,000 after buying an additional 4,456 shares during the period. Exxonmobil Investment Management Inc. TX boosted its stake in shares of DaVita HealthCare Partners by 8.0% in the first quarter. Exxonmobil Investment Management Inc. TX now owns 40,345 shares of the company’s stock worth $2,961,000 after buying an additional 2,983 shares during the period. Finally, Glenmede Trust Co. NA boosted its stake in shares of DaVita HealthCare Partners by 63.9% in the first quarter. Glenmede Trust Co. NA now owns 3,906 shares of the company’s stock worth $286,000 after buying an additional 1,523 shares during the period. 83.55% of the stock is owned by institutional investors and hedge funds.

Shares of DaVita HealthCare Partners Inc. (NYSE:DVA) opened at 66.72 on Friday. The stock has a 50 day moving average price of $66.56 and a 200-day moving average price of $73.08. DaVita HealthCare Partners Inc. has a one year low of $61.36 and a one year high of $78.94. The company has a market capitalization of $13.80 billion, a price-to-earnings ratio of 38.81 and a beta of 1.07.

DaVita HealthCare Partners (NYSE:DVA) last announced its earnings results on Monday, August 8th. The company reported $1.01 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.03. The business earned $3.72 billion during the quarter, compared to analyst estimates of $3.67 billion. DaVita HealthCare Partners had a return on equity of 16.48% and a net margin of 2.51%. DaVita HealthCare Partners’s revenue for the quarter was up 8.2% compared to the same quarter last year. During the same period last year, the company earned $0.95 EPS. On average, equities research analysts expect that DaVita HealthCare Partners Inc. will post $3.76 EPS for the current year.

A number of equities research analysts recently commented on DVA shares. Wells Fargo & Co. reaffirmed a “buy” rating on shares of DaVita HealthCare Partners in a research note on Saturday, June 4th. Zacks Investment Research raised DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $87.00 price objective for the company in a research note on Tuesday, July 5th. JPMorgan Chase & Co. lifted their price objective on DaVita HealthCare Partners from $74.00 to $75.00 and gave the stock a “neutral” rating in a research note on Tuesday, August 9th. TheStreet cut DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a research note on Monday, August 8th. Finally, Citigroup Inc. started coverage on DaVita HealthCare Partners in a research note on Tuesday, September 6th. They set a “neutral” rating and a $71.00 price objective for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $76.36.

In related news, COO Michael David Staffieri sold 20,262 shares of the firm’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $73.09, for a total transaction of $1,480,949.58. Following the completion of the transaction, the chief operating officer now directly owns 52,279 shares of the company’s stock, valued at approximately $3,821,072.11. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jeanine Marie Jiganti sold 4,620 shares of the firm’s stock in a transaction on Friday, July 1st. The stock was sold at an average price of $77.45, for a total value of $357,819.00. Following the transaction, the insider now directly owns 7,590 shares of the company’s stock, valued at $587,845.50. The disclosure for this sale can be found here. Corporate insiders own 2.10% of the company’s stock.

About DaVita HealthCare Partners

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita HealthCare Partners Inc. (NYSE:DVA).

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.